You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PO005LBA/#1579  A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-res…

Article metrics

Article menu

Download PDFPDF

Plenary 01: Oral Abstract Presentations
AS11. Ovarian cancer
PO005LBA/#1579  A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
Free

 

Online download statistics by month:

Online download statistics by month: November 2023 to October 2024

AbstractFullPdf
Nov 2023117019
Dec 2023109012
Jan 202462010
Feb 20245006
Mar 202454013
Apr 2024102012
May 20243007
Jun 202455010
Jul 202410206
Aug 20243806
Sep 202452013
Oct 20241300
Total7840114